Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-044 - nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): V. Hirsh
- Abstract
Loading...
-
+
O03 - NSCLC - Targeted Therapies I
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:J. Ross
- Coordinates: 10/28/2013, 10:30 - 12:00, Bayside Auditorium B, Level 1
-
+
O03.01 - GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients.
10:30 - 10:40 | Author(s): S.S. Ramalingam
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO07 - NSCLC - Targeted Therapies II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:T. John
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO07.13 - Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease
17:25 - 17:30 | Author(s): M. Schuler
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.10 - Poster Session 2 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.10-038 - nab-Paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC): analysis of predictive factors
09:30 - 09:30 | Author(s): V. Hirsh
- Abstract
Loading...
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.05 - Efficacy, safety, and patient-reported outcomes (PROs) with crizotinib versus chemotherapy in Asian patients in a phase III study of previously treated advanced ALK-positive non-small cell lung cancer (NSCLC)
11:15 - 11:25 | Author(s): M. Nishio
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-027 - A randomised, open-label phase II trial of volasertib as monotherapy and in combination with standard dose pemetrexed compared with pemetrexed monotherapy in second-line non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): P.M. Ellis
- Abstract
Loading...
-
+
Best of Posters - IASLC Selection - Part 2
- Type: Exhibit Showcase Session
- Track:
- Presentations: 4
- Coordinates: 10/30/2013, 09:55 - 10:25, Exhibit Hall, Ground Level
-
+
P2.11-024 - Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non- small Cell Lung Cancer (NSCLC)
10:00 - 10:05 | Author(s): S. Novello
- Abstract
Loading...
